Does Entresto Increase BNP?
Yes, Entresto (sacubitril/valsartan) does increase BNP levels, but the effect is variable and unpredictable across patients. 1
Mechanism and Clinical Evidence
Entresto's neprilysin inhibition component (sacubitril) blocks the enzyme that normally degrades BNP, leading to accumulation of this peptide in circulation. The FDA label explicitly states that in the PARADIGM-HF trial, Entresto increased plasma BNP (a neprilysin substrate) compared with enalapril 1. This is a direct pharmacodynamic consequence of neprilysin inhibition.
Magnitude and Variability of BNP Increase
The increase in BNP is highly variable between patients:
- Average increase: 19% after treatment initiation 2
- 18% of patients experience BNP doubling
- 6% of patients experience BNP tripling
- 14% of patients show no change at all 2
This heterogeneity is clinically important because it means you cannot predict how an individual patient's BNP will respond. The guideline evidence from JACC: Heart Failure (2020) emphasizes this rightward shift in BNP distribution is caused by treatment with sacubitril/valsartan 2.
Critical Clinical Distinction: BNP vs NT-proBNP
NT-proBNP is NOT a substrate for neprilysin and therefore decreases with Entresto treatment 3, 1. This creates a crucial clinical scenario:
- BNP increases (or remains elevated/variable)
- NT-proBNP decreases by 30-32% at weeks 4-12 4
The FDA label confirms that in PARADIGM-HF, Entresto decreased plasma NT-proBNP (not a neprilysin substrate) while increasing plasma BNP 1.
Clinical Implications for Monitoring
If Using BNP for Monitoring:
- Expect an increase or at minimum no decrease in the first 8-10 weeks after starting Entresto
- BNP remains prognostically valid despite the increase - higher levels still predict worse outcomes 5
- Rising BNP during treatment indicates worsening disease, not just drug effect 2
- Assay variability matters - different BNP assays show inconsistent responses to neprilysin inhibition 6
If Using NT-proBNP for Monitoring (Preferred):
- NT-proBNP should decrease with successful Entresto therapy
- Less clinical confusion since it's not affected by neprilysin inhibition 3, 2
- More predictable interpretation in the first 8-10 weeks of treatment 5
Common Pitfalls to Avoid
Do not interpret an elevated or rising BNP in the first 8-10 weeks of Entresto as treatment failure. This is the most common error. The increase reflects neprilysin inhibition working as intended, not worsening heart failure 2, 5.
Do not switch between BNP and NT-proBNP assays during Entresto treatment - they move in opposite directions, creating confusion 1.
Do not assume all patients will have BNP increases - 14% show no change, making individual patient responses unpredictable 2.
Prognostic Value Remains Intact
Despite the pharmacologic increase in BNP, both BNP and NT-proBNP retain their prognostic accuracy during Entresto treatment (C-statistics 63-67% for BNP, 64-70% for NT-proBNP) 5. Increases in either peptide during treatment are associated with worse outcomes, indicating true disease progression rather than just drug effect 5.
Bottom Line for Practice
Use NT-proBNP for monitoring patients on Entresto - it decreases with successful therapy and avoids the clinical confusion of BNP increases 3, 2. If your institution only measures BNP, establish a baseline steady-state concentration after 8-10 weeks of treatment and use the same assay consistently for serial monitoring 5, 7. Rising BNP after this stabilization period indicates worsening heart failure and warrants clinical action.